



an Open Access Journal by MDPI

# Studies on Strategies for Enhancing Vaccine Immunogenicity

Guest Editor:

#### Prof. Dr. David Scott McVey

School of Veterinary Medicine and Biomedical Sciences, University of Nebraska, P.O. Box 830905, Lincoln, NE 68583-0905, USA

Deadline for manuscript submissions: closed (31 October 2022)

### Message from the Guest Editor

The immunogenicity of a vaccine is determined by the characteristics of the specific antigens and the specific vaccine formulation used, as well as the characteristics of the immune response and other genetic factors of the target host. Therefore, variables such as antigen concentration and presentation, adjuvant requirements, delivery strategy, vaccine stability and handling, and manufacturing/distribution characteristics can affect population and individual host responses (and therefore, effectiveness).

We hope to encourage the introduction of recent developments in this Special Issue, focusing on understanding the molecular mechanisms that trigger protective immune responses from immunnization, and evaluating the contribution of adjuvants and immunomodulatory molecules to vaccine immunogenicity and induction of long lasting immunological memmory.

This Special Issue focuses on the latest research studies that define innovative strategies for enhancing vaccine immunogenicity. Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcomed. All manuscripts will follow standard journal peer-review practices.









an Open Access Journal by MDPI

# **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

# **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

### **Contact Us**

*Vaccines* Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/vaccines vaccines@mdpi.com